{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:43:20Z","timestamp":1777614200250,"version":"3.51.4"},"reference-count":31,"publisher":"European Respiratory Society (ERS)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2012,6,14]]},"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:p>NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium bromide in COPD airWays clinical Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52 weeks.<\/jats:p>\n                  <jats:p>\n                    Patients were randomised 2:1:1 to NVA237 50 \u03bcg, placebo or open-label tiotropium 18 \u03bcg for 52 weeks. Primary end-point was trough forced expiratory volume in 1 s (FEV\n                    <jats:sub>1<\/jats:sub>\n                    ) at 12 weeks.\n                  <\/jats:p>\n                  <jats:p>\n                    1,066 patients were randomised, 810 completed the study. At week 12, trough FEV\n                    <jats:sub>1<\/jats:sub>\n                    increased significantly by 97 mL with NVA237 (95% CI 64.6\u2013130.2; p&lt;0.001) and 83 mL with tiotropium (95% CI 45.6\u2013121.4; p&lt;0.001). Compared with placebo, NVA237 produced significant improvements in dyspnoea (Transition Dyspnoea Index at week 26; p=0.002) and health status (St George's Respiratory Questionnaire at week 52; p&lt;0.001). NVA237 significantly reduced the risk of moderate-to-severe COPD exacerbations by 34% (p=0.001) and the use of rescue medication (p=0.039),\n                    <jats:italic>versus<\/jats:italic>\n                    placebo. NVA237-placebo and tiotropium-placebo differences were comparable for all outcomes. Safety profiles were similar across groups.\n                  <\/jats:p>\n                  <jats:p>\n                    NVA237 50 \u03bcg provided significant improvements in lung function, dyspnoea, health status, exacerbations and rescue medication use,\n                    <jats:italic>versus<\/jats:italic>\n                    placebo, and was comparable to tiotropium. NVA237 can potentially be an alternative choice of LAMA for COPD patients.\n                  <\/jats:p>","DOI":"10.1183\/09031936.00040712","type":"journal-article","created":{"date-parts":[[2012,7,27]],"date-time":"2012-07-27T03:31:31Z","timestamp":1343359891000},"page":"1106-1114","source":"Crossref","is-referenced-by-count":155,"title":["Efficacy and safety of NVA237\n                    <i>versus<\/i>\n                    placebo and tiotropium in patients with COPD: the GLOW2 study"],"prefix":"10.1183","volume":"40","author":[{"given":"Edward","family":"Kerwin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Overend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay K.T.","family":"Alagappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"2024102021142753000_40.5.1106.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00082507"},{"key":"2024102021142753000_40.5.1106.2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD2011). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Available from www.goldcopd.org ."},{"issue":"Suppl. 50","key":"2024102021142753000_40.5.1106.3","first-page":"436s","article-title":"NVA237 has similar efficacy as tiotropium bromide against methacholine-induced bronchoconstriction and less systemic effect on cardiovascular variables in an anaesthetized rabbit model","volume":"28","author":"Cooper","year":"2006","journal-title":"Eur Respir J"},{"key":"2024102021142753000_40.5.1106.4","doi-asserted-by":"crossref","first-page":"530a","DOI":"10.1378\/chest.132.4_MeetingAbstracts.530a","article-title":"The inhaled antimuscarinic receptor antagonist, NVA237 (glycopyrrolate), has a favorable side-effect profile in a Brown Norway rat lung function model when compared with tiotropium","volume":"132","author":"Trifilieff","year":"2007","journal-title":"Chest"},{"key":"2024102021142753000_40.5.1106.5","doi-asserted-by":"crossref","unstructured":"Fogarty C Hattersley H Di Scala L . Bronchodilatory effects of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2011; 105;3: 337\u2013342.","DOI":"10.1016\/j.rmed.2010.10.021"},{"key":"2024102021142753000_40.5.1106.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.04.006"},{"key":"2024102021142753000_40.5.1106.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2010.04.005"},{"key":"2024102021142753000_40.5.1106.8","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-156"},{"key":"2024102021142753000_40.5.1106.9","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD2008). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Available from www.goldcopd.org ."},{"key":"2024102021142753000_40.5.1106.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00068503a"},{"issue":"Suppl. B","key":"2024102021142753000_40.5.1106.11","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.rmed.2005.09.011","article-title":"Measuring the effects of COPD on the patient","volume":"99","author":"Jones","year":"2005","journal-title":"Respir Med"},{"key":"2024102021142753000_40.5.1106.12","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903103006"},{"key":"2024102021142753000_40.5.1106.13","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.90336.2008b"},{"key":"2024102021142753000_40.5.1106.14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/COPD.S32451","article-title":"Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial","volume":"7","author":"Beeh","year":"2012","journal-title":"Int J COPD"},{"key":"2024102021142753000_40.5.1106.15","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00121404"},{"key":"2024102021142753000_40.5.1106.16","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2003.008730"},{"key":"2024102021142753000_40.5.1106.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530230038027"},{"key":"2024102021142753000_40.5.1106.18","first-page":"6","article-title":"What is an exacerbation of COPD","volume":"13","author":"Vestbo","year":"2004","journal-title":"Eur Respir Rev"},{"key":"2024102021142753000_40.5.1106.19","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2002.1334"},{"key":"2024102021142753000_40.5.1106.20","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.10.847"},{"key":"2024102021142753000_40.5.1106.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200712-1869OC"},{"key":"2024102021142753000_40.5.1106.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909883"},{"key":"2024102021142753000_40.5.1106.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805800"},{"key":"2024102021142753000_40.5.1106.24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/COPD.S2463","article-title":"Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD","volume":"3","author":"Tonnel","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102021142753000_40.5.1106.25","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-5-200509060-00007"},{"key":"2024102021142753000_40.5.1106.26","doi-asserted-by":"publisher","DOI":"10.1155\/2007\/192961"},{"key":"2024102021142753000_40.5.1106.27","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.1.47"},{"key":"2024102021142753000_40.5.1106.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00269802"},{"key":"2024102021142753000_40.5.1106.29","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.5.399"},{"key":"2024102021142753000_40.5.1106.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61298-8"},{"key":"2024102021142753000_40.5.1106.31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/COPD.S14680","article-title":"Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease","volume":"6","author":"Donohue","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.00040712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:38:41Z","timestamp":1740361121000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.00040712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,26]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,10,31]]},"published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1183\/09031936.00040712"],"URL":"https:\/\/doi.org\/10.1183\/09031936.00040712","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717962032.793466080","asserted-by":"object"}]},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,26]]}}}